2017-08-15 08:00:53 CEST

2017-08-15 08:00:53 CEST


English Finnish
Revenio Group Oyj - Managers' transactions

Revenio Group Corporation: Managers' transactions


Revenio Group Corporation, Managers' transactions, August 15, 2017 at 9:00 EET

Revenio Group Corporation: Managers' transactions

Revenio Group Oyj - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Joensuun Kauppa ja Kone Oy
Position: Closely associated person
(X) Legal person

(1):Closely associated person
Name: Kakkonen, Kyösti
Position: Member of the Board

Issuer: Revenio Group Oyj
LEI: 743700l27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700l27E0FWSXLKK04_20170814124020_1
____________________________________________

Transaction date: 2017-08-11
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009010912
Nature of the transaction: ACQUISITION


Transaction Details
(1): Volume: 1200 Unit price: 35,70700 EUR

Aggregated transactions
(1): Volume: 1200 Volume weighted average price: 35.70700 EUR



For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932

Distribution:
Nasdaq Helsinki
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit
for continuing operations standing at 30.1%. Revenio Group Corporation is listed
on Nasdaq Helsinki.


[]